Cover Image
市場調查報告書

OpportunityAnalyzer:尋常痤瘡 - 機會分析與預測

OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018

出版商 GlobalData 商品編碼 306632
出版日期 內容資訊 英文 177 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:尋常痤瘡 - 機會分析與預測 OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018
出版日期: 2014年06月20日 內容資訊: 英文 177 Pages
簡介

 主要6國(美國、法國、德國、義大利、西班牙、英國)的尋常痤瘡(粉刺)治療藥市場預測將由2012年的23億美金,擴大到2018年的28億美金,達到CAGR(年複合成長率)3.9%的成長。AndroScience發售ASC-J9、Galderma採用Epiduo、Photocure發售Visonac等,都是該成長的背景。

本報告提供尋常痤瘡(粉刺)的治療藥市場相關調查分析,提供您疾病概要,流行病學,目前治療選項,未滿足需求分析,機會分析,研究開發策略,開發平台評估等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 預後
  • 生活品質
  • 症狀

第4章 流行病學

  • 危險因素和共生病症
    • 家族病史讓粉刺的發病風險提升到4倍
    • 飲食習慣是粉刺最常見的風險因素
    • 抽煙和粉刺的關係尚不明確
    • 憂鬱症和不安是粉刺患者常見的共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
  • 預測的前提條件·手法
    • 美國
    • 法國
    • 德國
    • 義大利·西班牙
    • 英國
  • 尋常痤瘡的流行病學預測
    • 患病數量(總合)
    • 患病數量(總合):各年齡
    • 患病數量(總合):性別
    • 得病率(總合):年齡標準化
    • 患病數量(總合):嚴重度
  • 議論
    • 流行病學趨勢的考察
    • 分析的限制
    • 分析的優勢

第5章 目前治療選項

  • 概要
  • 產品簡介:領導品牌

第6章 與未滿足需求評估機會分析

  • 概要
  • 未滿足需求分析
  • 機會分析

第7章 研究開發(R&D)策略

  • 概要:生命週期管理策略
  • 臨床試驗設計

第8章 開發平台評估

  • 概要
  • 臨床開發中的有潛力藥劑
  • 創新的初期階段的方法

第9章 開發平台評估分析

  • 主要開發平台藥物臨床基準
  • 主要開發平台藥物的商業基準
  • 競爭評估
  • 銷售額的5年預測
    • 美國
    • EU5個國家

第10章 附錄

圖表

目錄
Product Code: GDHC011POA

Despite its considerable patient population, the acne market has been overlooked and remained stagnant for the last decade. There has been a lack of research efforts due to the perception of a poor return on investment for topical treatments, the mainstay of acne therapy. There is an array of treatment options for acne, though with the exception of isotretinoin, most only provide symptomatic relief as opposed to a curative or disease-modifying solution. However, isotretinoin is unable to serve a significant proportion of the acne market owed to its teratogenic nature, making its prescription for women of child-bearing age problematic.

In the past decade, there has been a shift in the acne market, with greater appreciation of its patient pool and potential for a lucrative payoff. Furthermore, there has been greater stress put on the social and psychological implications of the disease, which impact patients' quality of life. As a result, R&D investments have been initiated by key pharmaceutical players.

Key strategies underway in the acne market include -

  • Drive for combination therapies, for example, Galderma's Epiduo (adapalene and benzoyl peroxide), which continues to experience rapid uptake.
  • Expansion of the market into the pediatric population and for late-onset acne in women.
  • A push towards disease-modifying therapies; for example, launch of AndroScience's ASC-J9 androgen receptor degradation enhancer is anticipated to be a game-changer and is expected to rival isotretinoin, the current market leader for severe acne.

Highlights

Key Questions Answered

  • How will the US and 5EU acne markets evolve over the forecast period from 2012 to 2018 in terms of sales and patient numbers?
  • How will the launch of late-stage pipeline therapies such as ASC-J9 and Visonac shape the future treatment landscape?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare to one another and against existing treatment options?
  • Why has there been a void of R&D interest from Big Pharma in this highly populated dermatology indication?
  • What are the remaining unmet needs and opportunities for drug developers within the acne space?

Key Findings

  • The main drivers of growth in the acne market during the 2012-2018 forecast period include the launch of AndroScience's ASC-J9, a therapeutic that is highly anticipated in the previously stagnant acne market and will make hormonal therapies available to males with acne, the continued success and uptake of Galderma's Epiduo, and the launch of Photocure's Visonac; potentially the first photodynamic therapy for use in acne.
  • The lack of dedicated R&D programs in acne has been attributed to pharmaceutical companies viewing topicals, the mainstay of acne therapy, as being inexpensive, with a poor return on investment. Instead, R&D strategies have centered on reformulations of existing products and/or fixed-dose combination therapies, acquisitions of key dermatology products by Big Pharma, and label expansions into the previously untapped pediatric market. Targeting the pediatric market is a strategy that GlobalData expects will be used by other dermatology companies during the coming decade.
  • A continued unmet need for acne is the need for new and innovative products to treat the underlying condition. Ideally, these products should be molecules that can specifically target critical pathways in the acne pathophysiology. Given the acne market's substantial patient pool (estimated to be 103.9 million patients in the US and 5EU) and increasing understanding of the disease's pathophysiology, GlobalData expects continued interest in the acne market from biotechs and pharmaceutical companies over the coming decade.

Scope

  • Overview of acne, including epidemiology, etiology, pathophysiology, symptoms, and current treatment options.
  • Annualized acne prescription therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2018.
  • Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and benchmarking analysis for the acne prescription therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs. Accompanied by an interactive clinical and commercial benchmarking analysis tool.
  • Analysis of the current and future market competition in the US and 5EU acne prescription therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Additionally a list of acquisition targets included in the early-stage pipeline products list.
  • Develop business strategies by understanding the trends shaping and driving the US and 5EU acne prescription therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US and 5EU acne prescription therapeutics markets in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track therapy sales in the US and 5EU acne prescription therapeutics markets from 2012-2018.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
  • 3.2. Prognosis
  • 3.3. Quality of Life
  • 3.4. Symptoms

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
    • 4.1.1. A family history of acne increases the risk of acne by four times
    • 4.1.2. Diet is the most common aggravating factor of acne
    • 4.1.3. The relationship between smoking and acne is unclear
    • 4.1.4. Depression and anxiety are common comorbidities in acne patients
  • 4.2. Global Trends
    • 4.2.1. US
    • 4.2.2. 5EU
  • 4.3. Forecast Methodology
    • 4.3.1. Sources Used
    • 4.3.2. Sources Not Used
  • 4.4. Forecast Assumptions and Methods
    • 4.4.1. US
    • 4.4.2. France
    • 4.4.3. Germany
    • 4.4.4. Italy and Spain
    • 4.4.5. UK
  • 4.5. Epidemiology Forecast for Acne (2012-2022)
    • 4.5.1. Total Prevalent Cases of Acne Vulgaris
    • 4.5.2. Age-Specific Total Prevalent Cases of Acne Vulgaris
    • 4.5.3. Sex-Specific Total Prevalent Cases of Acne Vulgaris
    • 4.5.4. Age-Standardized Total Prevalence of Acne Vulgaris
    • 4.5.5. Total Prevalent Cases of Acne Vulgaris by Severity
  • 4.6. Discussion
    • 4.6.1. Conclusions on Epidemiological Trends
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands
    • 5.2.1. Tretinoin (numerous brand and generic names)
    • 5.2.2. Isotretinoin
    • 5.2.3. Adapalene (numerous generic names)
    • 5.2.4. Benzoyl Peroxide (numerous generic names)
    • 5.2.5. Azelaic Acid (numerous generic names)
    • 5.2.6. Hormonal Therapy (numerous brand and generic names)
    • 5.2.7. Epiduo (adapalene and benzoyl peroxide)
    • 5.2.8. Tretinoin and Clindamycin Phosphate (numerous brand names)
    • 5.2.9. Benzoyl Peroxide and Clindamycin Phosphate (numerous brand and generic names)
    • 5.2.10. Benzoyl Peroxide and Erythromycin (numerous brand and generic names)
    • 5.2.11. Isotretinoin and Erythromycin (numerous brand and generic names)
    • 5.2.12. Zineryt (erythromycin and zinc acetate)

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Unmet Needs Analysis
    • 6.2.1. Inadequate Investment in Innovative Drugs
    • 6.2.2. Improved Compliance
    • 6.2.3. Cost-Prohibitive Products
    • 6.2.4. Increased Patient and Caregiver Awareness
    • 6.2.5. Non-Teratogenic Treatment Options for Female Acne Patients of Childbearing Age
  • 6.3. Opportunity Analysis
    • 6.3.1. Investment in Novel Systemic Compounds
    • 6.3.2. Affordable and Accessible Combination Treatment Options
    • 6.3.3. Holistic Management of Acne Patients
    • 6.3.4. Exploring Photodynamic Therapy as a Potential Treatment for Acne

7. R&D Strategies

  • 7.1. Overview - Lifecycle Management Strategies
    • 7.1.1. Reformulation Strategies
    • 7.1.2. M&A in the Dermatology Market
    • 7.1.3. Label Expansion into Pediatric Population
  • 7.2. Clinical Trial Design
    • 7.2.1. Current Clinical Trial Design
    • 7.2.2. Limitations of Current Clinical Trial Design
    • 7.2.3. Future Outlook in Acne Clinical Trial Design

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. ASC-J9
    • 8.2.2. Visonac (methyl aminolevulinate)
  • 8.3. Innovative Early-Stage Approaches
    • 8.3.1. Anti-Inflammatory Drugs
    • 8.3.2. Vaccine Development
    • 8.3.3. Neuropeptides
    • 8.3.4. Phages

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line Five-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Acne Vulgaris Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Author/Reviewer
    • 10.6.3. Reviewer
    • 10.6.4. Epidemiologist
    • 10.6.5. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Acne
  • Table 2: Classification of Acne Severity
  • Table 3: 6MM, Sources of Acne Prevalence Data
  • Table 4: 6MM, Sources of Acne Severity Data
  • Table 5: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10-44 Years, Both Sexes, N (Millions), 2012-2022
  • Table 6: 6MM, Total Prevalent Cases of Acne Vulgaris, by Age, Both Sexes, N (Millions), (Row %), 2012
  • Table 7: 6MM, Total Prevalent Cases of Acne Vulgaris, by Sex, Ages 10-44 Years, N (Row %), 2012
  • Table 8: 6MM, Total Prevalent Cases of Acne Vulgaris by Severity, Ages 10-44 Years, Both Sexes, N (Millions) (Row %), 2012
  • Table 9: Commonly Used Treatments for the Management of Acne
  • Table 10: Product Profile - Tretinoin
  • Table 11: Tretinoin SWOT Analysis, 2014
  • Table 12: Product Profile - Isotretinoin
  • Table 13: Isotretinoin SWOT Analysis, 2014
  • Table 14: Product Profile - Adapalene
  • Table 15: Adapalene SWOT Analysis, 2014
  • Table 16: Product Profile - Benzoyl Peroxide
  • Table 17: Benzoyl Peroxide SWOT Analysis, 2014
  • Table 18: Product Profile - Azelaic Acid
  • Table 19: Azelaic Acid SWOT Analysis, 2014
  • Table 20: Product Profile - Hormonal Therapy
  • Table 21: Hormonal Therapy SWOT Analysis, 2014
  • Table 22: Product Profile - Epiduo
  • Table 23: Epiduo SWOT Analysis, 2014
  • Table 24: Product Profile -Tretinoin and Clindamycin Phosphate
  • Table 25: Tretinoin and Clindamycin Phosphate SWOT Analysis, 2014
  • Table 26: Product Profile - Benzoyl Peroxide and Clindamycin Phosphate
  • Table 27: Benzoyl Peroxide and Clindamycin Phosphate SWOT Analysis, 2014
  • Table 28: Product Profile - Benzoyl Peroxide and Erythromycin
  • Table 29: Benzoyl Peroxide and Erythromycin SWOT Analysis, 2014
  • Table 30: Product Profile - Isotretinoin and Erythromycin
  • Table 31: Isotretinoin and Erythromycin SWOT Analysis, 2014
  • Table 32: Product Profile - Zineryt
  • Table 33: Zineryt SWOT Analysis, 2014
  • Table 34: Overall Unmet Needs in Acne - Current Level of Attainment
  • Table 35: Acne - Late-Stage Pipeline, 2014
  • Table 36: Product Profile - ASC-J9
  • Table 37: ASC-J9 SWOT Analysis, 2014
  • Table 38: Product Profile - Visonac (methyl aminolevulinate)
  • Table 39: Visonac SWOT Analysis, 2014
  • Table 40: Early-Stage Pipeline Products in Acne, April 2014
  • Table 41: Clinical Benchmark for Acne, 2014
  • Table 42: Commercial Benchmark for Acne, 2014
  • Table 43: Top-Line Sales Forecasts ($m) for Acne, 2012-2018
  • Table 44: Key Events Impacting Sales for Acne, 2012-2018
  • Table 45: Acne Market - Drivers and Barriers, 2012-2018
  • Table 46: Key Launch Dates

List of Figures

  • Figure 1: Pathophysiology of Acne
  • Figure 2: Acne Grades and Correlation with Scarring
  • Figure 3: Acne Symptoms
  • Figure 4: Classification of Acne Severity
  • Figure 5: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10-44 Years, Both Sexes, N (Millions), 2012-2022
  • Figure 6: 6MM, Total Prevalent Cases of Acne Vulgaris, by Age, Both Sexes, N (Millions), 2012
  • Figure 7: 6MM, Total Prevalent Cases of Acne Vulgaris, by Sex, Ages 10-44 Years, N (Millions), 2012
  • Figure 8: 6MM, Age-Standardized Total Prevalence of Acne Vulgaris, Ages 10-44 Years, 2012
  • Figure 9: 6MM, Total Prevalent Cases of Acne Vulgaris by Severity, Ages 10-44 Years, Both Sexes, N (Millions), 2012
  • Figure 10: Acne Treatment Algorithm
  • Figure 11: Competitive Assessment of Acne Therapies and Late-Stage Pipeline Agents in Acne, 2012-2018
  • Figure 12: Global Sales for Acne by Region, 2012-2018
Back to Top